Journal
INTERNATIONAL JOURNAL OF PHARMACEUTICS
Volume 345, Issue 1-2, Pages 154-162Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.ijpharm.2007.05.062
Keywords
macrophage; moxifloxacin; M. Tuberculosis; nanoparticles; poly(butyl cyanoacrylate)
Categories
Funding
- NIAID NIH HHS [R21 AI 055284-A] Funding Source: Medline
Ask authors/readers for more resources
Macrophages in the lungs are the most important cell type supporting replication of Mycobacterium tuberculosis in humans. The objective of this study was to investigate whether the effect of moxifloxacin against M. tuberculosis residing in macrophages could be improved by encapsulation of the drug in the biodegradable nanoparticles, which are known to accumulate in macrophages upon intravenous administration. To accomplish this, moxifloxacin was encapsulated in poly(butyl cyanoacrylate) (PBCA) nanoparticles. Encapsulated moxifloxacin accumulated in macrophages approximately three-fold times more efficiently than the free drug, and was detected in the cells for at least six times longer than free moxifloxacin at the same extracellular concentration. Inhibition of intracellular M. tuberculosis growth with encapsulated moxifloxacin was achieved at the concentration of 0.1 mu g/ml, whereas the same effect with free MX required a concentration of 1 mu g/ml. Nanoparticles observed within the macrophage cytoplasm were distributed throughout the cytoplasm, sometimes in the vicinity of intracellular bacteria. (c) 2007 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available